Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT.

ABSTRACT:

Purpose

Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in urothelial carcinoma (UC). We aimed to evaluate the feasibility of 68Ga-HER2 affibody PET/CT in assessing HER2 expression and tumor heterogeneity, and to explore its utility for guiding HER2-targeted therapy in UC.

Patients and methods

Thirty-two patients with UC who underwent 68Ga-HER2-affibody and 18F-FDG-PET/CT were prospectively recruited from September 2024 to April 2025. Semiquantitative PET/CT parameters (SUVmax, SUVmean, TMR, HER2-TV/MTV, and TL-HER2/TLG) were analyzed across HER2 statuses. Intrapatient heterogeneity of SUVmax across lesions was assessed by the coefficient of variation (CV).

Results

HER2-positive patients demonstrated significantly higher SUVmax, SUVme

SUBMITTER: Tao Z 

PROVIDER: S-EPMC12771973 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature